Announcements Trials
Browse Landscape

Phase

Phase 2/3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Lung Neoplasms 23Carcinoma, Non-Small-Cell Lung 16Ovarian Neoplasms 12Fallopian Tube Neoplasms 11Carcinoma, Hepatocellular 10Urinary Bladder Neoplasms 7Pancreatic Neoplasms 7Melanoma 7Colorectal Neoplasms 7Carcinoma, Renal Cell 7Triple Negative Breast Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Neoplasm Metastasis 5Mycosis Fungoides 5Endometrial Neoplasms 5Breast Neoplasms 5Lymphoma, T-Cell, Cutaneous 4Glioblastoma 4Thyroid Neoplasms 3Sezary Syndrome 3Nasopharyngeal Carcinoma 3Multiple Myeloma 3Mouth Neoplasms 3Lymphoma, T-Cell 3Colonic Neoplasms 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Carcinoma 3Brenner Tumor 3Brain Neoplasms 3

Interventions

Magnetic Resonance Spectroscopy 13Cisplatin 12Specimen Handling 11pembrolizumab 10Radiotherapy, Intensity-Modulated 7Cetuximab 7Platinum 61,2-diaminocyclohexaneplatinum II citrate 6Taxes 4Surgical Procedures, Operative 4Radiotherapy 4Paclitaxel 4Carboplatin 4Biopsy 4(225)Ac-DOTA-c(RGDyK) 4Radiation 3Chemoradiotherapy 3ipatasertib 2X-Rays 2Surveys and Questionnaires 2Interviews as Topic 2Immunoglobulin G 2Fluorodeoxyglucose F18 2Docetaxel 2Disulfides 2sacituzumab govitecan 1peposertib 1merphos 1durvalumab 1dehydroftorafur 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hypopharyngeal Neoplasms × Immunoglobulin G × 1 year × Clear all
NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03258554 2026-06-02

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

Phase 2/3 Completed
196 enrolled 31 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡